Welcome to our dedicated page for SOPHiA GENETICS SA SEC filings (Ticker: SOPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SOPHiA GENETICS SA filings document the disclosures of a foreign private issuer that reports through Form 6-K and related registration statements. The company’s filings include unaudited interim condensed consolidated financial statements, management discussion and analysis, press releases on operating results, and Swiss annual report materials tied to its AI-driven precision medicine software business.
Other filings cover annual general meeting notices, proxy materials, shareholder voting documents, incorporation by reference into Form F-3 and Form S-8 registration statements, and capital-structure matters such as credit-agreement amendments, term loan commitments, warrants, and ordinary-share purchase rights.
SOPHiA GENETICS SA director Troy Cox received new equity awards tied to his board service. He was granted 19,724 restricted stock units, each representing one ordinary share valued at $5.46, bringing his direct holdings to 328,743 ordinary shares.
He also received options to purchase 28,818 ordinary shares at an exercise price of $5.46 per share, expiring on June 18, 2036, increasing his option holdings to 252,809. Both the RSUs and options were granted on June 18, 2026 and vest 100% at the date of the company’s next scheduled annual meeting of shareholders, contingent on his continued service.
SOPHiA GENETICS SA director Kathy L. Hibbs received new equity awards as part of her compensation. She was granted 19,724 restricted stock units, each representing one ordinary share, at a reference price of $5.46 per share. Following this award, she directly holds 109,492 ordinary shares.
She also received options to buy 28,818 ordinary shares at an exercise price of $5.46 per share, expiring on June 18, 2036, bringing her total option holdings to 218,569 share options. Both the RSUs and options were granted on June 18, 2026 and vest 100% at the date of the company’s next scheduled annual meeting of shareholders, subject to her continued service.
SOPHiA GENETICS SA director Vincent Ossipow received equity compensation consisting of restricted stock units and options. On June 18, 2026 he was granted 19,724 RSUs, each representing one ordinary share, and 28,818 share options with a $5.46 exercise price. Both the RSUs and options vest 100% at the date of the company’s next scheduled annual shareholder meeting, subject to his continued service. Following these awards, he directly holds 522,860 ordinary shares and 138,569 options.
SOPHiA GENETICS SA director Jean-Michel Cossery reported receiving new equity awards as part of his compensation. He was granted 19,724 restricted stock units, each representing one ordinary share, and 28,818 share options with a conversion price of $5.46 per share.
Both the RSUs and options were granted on June 18, 2026 and vest 100% at the date of the company’s next scheduled annual meeting of shareholders, subject to his continued service. Following these awards, Cossery directly holds 206,212 ordinary shares and 138,449 options.
SOPHiA GENETICS SA director Didier Hirsch received new equity awards as part of his compensation. He was granted 19,724 Ordinary Shares in the form of restricted stock units valued at $5.46 per share, bringing his direct share holdings to 240,220 Ordinary Shares.
He also received options to buy 28,818 Ordinary Shares at an exercise price of $5.46 per share, with 218,569 options held after the grant. Both the RSUs and the options were granted on June 18, 2026 and vest 100% at the date of the company’s next scheduled annual meeting of shareholders, subject to his continued service.
SOPHiA GENETICS completed an underwritten public offering of 12,104,900 ordinary shares at $4.75 per share, raising gross proceeds of about $57.5 million before fees and expenses. The deal included 1,578,900 additional shares sold after underwriters fully exercised their option, and closed on June 18, 2026.
The shares were issued under an effective Form F-3 shelf registration, with TD Securities leading a syndicate of underwriters. All shares were sold by the company, providing new primary capital and diluting existing shareholders while strengthening the balance sheet.
SOPHiA GENETICS SA reported the results of its June 2026 annual general meeting, where shareholders approved all agenda items with strong majorities. They accepted the 2025 management and financial statements and discharged the board and executive committee from liability for 2025.
Shareholders approved carrying forward the 2025 net loss of CHF 52,825,053, leading to a total accumulated loss of CHF 403,784,733. They re-elected all incumbent directors, confirmed PricewaterhouseCoopers as statutory auditor for 2026, and elected PHC Notaires as independent proxy through the 2027 meeting.
The meeting approved maximum aggregate compensation of USD 1,942,600 for the board and fixed and variable executive compensation caps of USD 3,606,907 and USD 17,500,000. Shareholders also approved amendments to the Articles of Association, including an increase in conditional share capital for employee participation and detailed provisions on capital range, financing-related conditional capital, and ownership and voting limits.
SOPHiA GENETICS is offering 10,526,000 ordinary shares at a public offering price of $4.75 per share, with an underwriters’ option to purchase up to an additional 1,578,900 ordinary shares for 30 days after this prospectus supplement. The offering is expected to raise gross proceeds of approximately $49,998,500 before underwriting discounts and commissions.
Net proceeds to the company are shown as approximately $46,998,590 (before expenses) and estimated net proceeds are approximately $45.9 million. Shares outstanding used for dilution calculations are listed as 71,790,366 ordinary shares as of March 31, 2026. The ordinary shares trade on Nasdaq under the symbol SOPH.
SOPHiA GENETICS SA Chief Scientific Officer Xu Zhenyu sold 4,000 Ordinary Shares in an open-market transaction. The shares were sold at a weighted average price of $5.0141 per share across multiple trades within a $4.90 to $5.13 range. After this transaction, Xu Zhenyu directly holds 622,280 Ordinary Shares. The sale was executed pursuant to a duly adopted trading plan under Rule 10b5-1(c), indicating the trades were pre-scheduled rather than discretionary.
SOPHiA GENETICS is offering ordinary shares pursuant to a preliminary prospectus supplement dated June 16, 2026. The supplement states the company has granted the underwriters a 30-day option to purchase additional ordinary shares at the public offering price less underwriting discounts and commissions. The company notes 71,790,366 ordinary shares outstanding as of March 31, 2026 and discloses a last reported Nasdaq sale price of $5.01 per share on June 15, 2026. The prospectus supplement describes intended uses of net proceeds for working capital and general corporate purposes, including research and development, sales and marketing, collaborations, regulatory clearances and possible in-licensing or acquisitions; it warns of dilution, lock-up agreements and the potential for future sales to affect the market price.